Table 5 Studies of TXA in hip fracture procedures
Study | Design | Sample | Surgery type | TXA regimen | Conclusion |
|---|---|---|---|---|---|
Zufferey 2010 | RCT | 110 | Arthroplasty, DHS and IMN | 15 mg/kg prior to surgery and 3 h later | TXA effective but not safe |
Lee 2015 | Cohort study | 271 | Hemiarthroplasty | 1 g bolus preoperative | TXA safe and cost-effective |
Sadeghi 2007 | RCT | 67 | Internal fixation and hemiarthroplasty | 15 mg/kg preoperative | TXA significantly reduces blood loss |
Vijay 2013 | RCT | 90 | Internal fixation and arthroplasty | 10 mg/kg | TXA reduces blood loss and transfusion requirement |
Baruah 2016 | RCT | 60 | DHS | 15 mg/kg preoperative | TXA safe and effective |
Tengberg 2016 | RCT | 72 | IMN | 1 g preoperative and 3 g infusion for 24 h | TXA effective for reducing blood loss, but safety should be investigated further |
Mohib 2015 | RCT | 100 | – | 15 mg/kg preoperative and 3 h later | TXA effective and safe |
Emara 2014 | RCT | 60 | Hemiarthroplasty | 10 mg/kg prior to surgery and 5 mg/kg/h infusion until end of surgery, or 1.5 g for topical irrigation | Topical TXA safer than intravenous TXA |
Watts 2017 | RCT | 138 | Hemiarthroplasty or THA | 2 dose of 15 mg/kg IV TXA before incision and at wound closure | TXA was safe to reduce blood loss with a tendency for decreased transfusion |
Current study | Cohort study | 609 | Hemiarthroplasty | 15 mg/kg prior to incision | TXA effective and safe |